The Johnson-Biden Foundation has announced a new initiative that will help US states expand vaccine production, and pave the way for the company’s bioburden patents to be given tax credits.
“The best way to protect American workers, small businesses, and jobs is to make it easier for Americans to get the vaccines they need,” says Governor Brian Schweitzer (D-MT). “With the support of the Johnson-Biden Foundation, we will ensure that all Americans, including the most vulnerable, have access to a flu vaccine that is safe and effective.”
The new initiative will cover two major areas: expand vaccine production in Florida, and grant tax credits to bioburden patent holders, which in turn will help expand production.
The vaccination requirement for elementary and middle school children in Florida will be widened beginning this fall, according to a press release from the foundation. As flu-related deaths increase, the government intends to provide tens of millions of doses of the influenza vaccine to students entering school during the 2018-2019 school year. This will allow the state to boost vaccine production to a minimum before introducing the immunization requirement for all school children.
In terms of patents and tax credits, the Johnson-Biden Foundation recently signed an agreement with the vaccine manufacturing group Amphicare to award bioburden patent holders two years of what are called “W-2” tax credits, after discovering that the company had held two patents on a bioburden vaccine. Those patents, which were granted in 2012 and have been the basis for all economic activity at Amphicare since 2014, will be split into two patent splits: one group of patents for a hepatitis B bioburden vaccine, and one for a hepatitis C bioburden vaccine. In total, the tax credits for this company amount to more than $225 million.
The two bioburden patents, which can result in a substantial tax liability for companies, were awarded after the US Patent and Trademark Office (USPTO) began analyzing samples of Amphicare’s products that the company had introduced to the market in 2012.
“The Johnson-Biden Foundation could not be more pleased with the results we have seen this past year,” says Director Bruce Baum, Ph.D. “Not only have Amphicare products become available for the first time to millions of Americans, but we’ve also been able to work with the Johnson-Biden Foundation to enable bioburden patent holders to realize some of the benefits they had hoped for, and it all came together thanks to a massive public-private partnership.”
The foundation’s agreement with Amphicare was the first licensing agreement of its kind, creating a precedent for future partnership agreements. Johnson-Biden wants to expand the standard to include all bioburden patents to further promote innovation and secure more partnerships for bioburden vaccine production.
“Today, we’re only touching the tip of the iceberg in terms of innovative partnerships that can make more products available for people,” says Baum. “And we look forward to partnering with more bioburden patent holders in the coming years.”
Source: McGraw Hill, Johnson-Biden Foundation